返回 Agendas
FDA GCP Compliance and Enforcement Updates
Session Chair(s)
Sean Kassim, PhD
Director, Office of Study Integrity and Surveillance, OTS, CDER
FDA, United States
This FDA cross-center session will provide updates on GCP compliance and enforcement activities with a special focus on eClinical technologies in the conduct of clinical trials.
Learning Objective : Describe the FDA's recent GCP compliance and enforcement activities/trends across CBER, CDER, CDRH; Discuss new and applicable guidances, policy and considerations in conducting clinical research; Summarize activities in preparing for an FDA GCP site inspection.
Speaker(s)
CDER Perspective
Sean Kassim, PhD
FDA, United States
Director, Office of Study Integrity and Surveillance, OTS, CDER
CBER Perspective
Bhanu Kannan, MSc
FDA, United States
Consumer Safety Officer, Office of Compliance and Biologics Quality, CBER
CDRH Perspective
Adam C. Donat, MS
FDA, United States
Deputy Division Director, Clinical Science and Quality, OPEQ, CDRH
注册方法
Registration override should work.